CASI PHARMACEUTICALS HOLDINGS, INC.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing, 100025
People’s Republic of China
February 9, 2023
VIA EDGAR
Mr. Joshua Gorsky
Division of Corporation Finance
Office of Life Sciences
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | CASI Pharmaceuticals Holdings, Inc. |
Registration Statement on Form F-4, as amended
File No. 333-269479
Dear Mr. Gorsky:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), CASI Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form F-4 (File No. 333-269479) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time on Monday, February 13, 2023, or as soon thereafter as may be practicable.
In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com if you have any questions. Thank you very much.
[Signature page follows]
| Sincerely, | |||
| CASI Pharmaceuticals Holdings, Inc. | |||
| By: | /s/ Kun Qian | ||
| Name: | Kun Qian | ||
| Title: | Principal Executive Officer | ||
